Skip to content

Study · Animal study (in vivo) · dog, pig and rat · 2007

15 results

Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.

Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P

Basic & clinical pharmacology & toxicology1 Jan 2007Cited by 22 (Europe PMC)

PMID17214611 (opens in a new tab)DOI10.1111/j.1742-7843.2007.00008.x (opens in a new tab)PepBankPUB-17214611
Publisher pagePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In animals, the modification prolonged the in vivo plasma elimination kinetics of immunoreactive TH9507 compared with natural hGRF1-44NH2.

    In plain wordsIn animals, TH9507 stayed in the blood longer than the natural peptide.

    Peptide
    Tesamorelin
    Outcome
    IncreaseIn vivo plasma elimination kinetics
    Study

    n: not reported in source

    Comparator
    Natural hGRF1-44NH2
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to natural hGRF1-44NH2, the modification slowed the in vitro degradation of the peptide in rat, dog and human plasma and prolonged the in vivo plasma elimination kinetics of immunoreactive TH9507
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In pigs, rats and dogs, repeated daily TH9507 injections markedly increased plasma growth hormone.

    In plain wordsIn pigs, rats and dogs, repeated daily TH9507 injections markedly raised growth hormone in the blood.

    Peptide
    Tesamorelin
    Outcome
    IncreasePlasma growth hormone
    Study

    pig, rat and dogn: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    up to 600 microg/kg · intravenous or subcutaneous · daily repeat injectionsAs given in this study (pig, rat and dog).

    Source sentences

    Summary
    Plasma growth hormone and insulin-like growth factor-1 (IGF-1) markedly increased in pigs, rats and dogs after daily repeat intravenous or subcutaneous injections of TH9507 at doses up to 600 microg/kg.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In pigs, rats and dogs, repeated daily TH9507 injections markedly increased plasma IGF-1.

    In plain wordsIn pigs, rats and dogs, repeated daily TH9507 injections markedly raised IGF-1 in the blood.

    Peptide
    Tesamorelin
    Outcome
    IncreasePlasma IGF-1
    Study

    pig, rat and dogn: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    up to 600 microg/kg · intravenous or subcutaneous · daily repeat injectionsAs given in this study (pig, rat and dog).

    Source sentences

    Summary
    Plasma growth hormone and insulin-like growth factor-1 (IGF-1) markedly increased in pigs, rats and dogs after daily repeat intravenous or subcutaneous injections of TH9507 at doses up to 600 microg/kg.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In rats and dogs, TH9507 for up to 4 months significantly increased body weight gain, not in a dose-related way.

    In plain wordsIn rats and dogs, TH9507 for up to 4 months increased weight gain, but not in step with the dose.

    Peptide
    Tesamorelin
    Outcome
    IncreaseBody weight gain
    Study

    rat and dogn: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · up to 4 monthsAs given in this study (rat and dog).

    Source sentences

    Summary
    Subchronic toxicity studies in rats and dogs with TH9507 treatment for up to 4 months showed a significant, but not dose-related, increase in body weight gain associated with increased biomarker response.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In rats and dogs, TH9507 was well tolerated.

    In plain wordsIn rats and dogs, TH9507 was well tolerated.

    Peptide
    Tesamorelin
    Outcome
    No significant changeTolerability in rats and dogs
    Study

    rat and dogn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although TH9507 was well tolerated by both rats and dogs, a more pronounced anabolic effect and more evident (reversible) adverse effects (liver and kidney findings, anaemia, clinical chemistry changes, organ weight effects) were observed in dogs after repeat daily subcutaneous injections, which wer…
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In dogs given repeat daily subcutaneous TH9507, the anabolic effect was more pronounced than in rats.

    In plain wordsIn dogs given repeated daily TH9507 injections, the growth-promoting effect was stronger than in rats.

    Peptide
    Tesamorelin
    Outcome
    IncreaseAnabolic effect in dogs
    Study

    dogn: not reported in source

    Comparator
    Rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · repeat daily injectionsAs given in this study (dog).

    Source sentences

    Summary
    a more pronounced anabolic effect and more evident (reversible) adverse effects (liver and kidney findings, anaemia, clinical chemistry changes, organ weight effects) were observed in dogs after repeat daily subcutaneous injections
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In dogs given repeat daily subcutaneous TH9507, reversible liver findings were observed.

    In plain wordsIn dogs given repeated daily TH9507 injections, liver findings appeared that went away again.

    Peptide
    Tesamorelin
    Outcome
    Direction not reportedLiver findings in dogs
    Study

    dogn: not reported in source

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated · subcutaneous · repeat daily injectionsAs given in this study (dog).

    Source sentences

    Summary
    more evident (reversible) adverse effects (liver and kidney findings, anaemia, clinical chemistry changes, organ weight effects) were observed in dogs after repeat daily subcutaneous injections
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In dogs given repeat daily subcutaneous TH9507, reversible kidney findings were observed.

    In plain wordsIn dogs given repeated daily TH9507 injections, kidney findings appeared that went away again.

    Peptide
    Tesamorelin
    Outcome
    Direction not reportedKidney findings in dogs
    Study

    dogn: not reported in source

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneous · repeat daily injectionsAs given in this study (dog).

    Source sentences

    Summary
    more evident (reversible) adverse effects (liver and kidney findings, anaemia, clinical chemistry changes, organ weight effects) were observed in dogs after repeat daily subcutaneous injections
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In dogs given repeat daily subcutaneous TH9507, reversible anaemia was observed.

    In plain wordsIn dogs given repeated daily TH9507 injections, anaemia appeared that went away again.

    Peptide
    Tesamorelin
    Outcome
    Direction not reportedAnaemia in dogs
    Study

    dogn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · repeat daily injectionsAs given in this study (dog).

    Source sentences

    Summary
    more evident (reversible) adverse effects (liver and kidney findings, anaemia, clinical chemistry changes, organ weight effects) were observed in dogs after repeat daily subcutaneous injections
  10. 10AnimalAnimal study (in vivo)Safety outcome

    In dogs given repeat daily subcutaneous TH9507, reversible clinical chemistry changes were observed.

    In plain wordsIn dogs given repeated daily TH9507 injections, blood test changes appeared that went away again.

    Peptide
    Tesamorelin
    Outcome
    Direction not reportedClinical chemistry changes in dogs
    Study

    dogn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · repeat daily injectionsAs given in this study (dog).

    Source sentences

    Summary
    more evident (reversible) adverse effects (liver and kidney findings, anaemia, clinical chemistry changes, organ weight effects) were observed in dogs after repeat daily subcutaneous injections
  11. 11AnimalAnimal study (in vivo)Safety outcome

    In dogs given repeat daily subcutaneous TH9507, reversible organ weight effects were observed.

    In plain wordsIn dogs given repeated daily TH9507 injections, organ weight changes appeared that went away again.

    Peptide
    Tesamorelin
    Outcome
    Direction not reportedOrgan weight effects in dogs
    Study

    dogn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · repeat daily injectionsAs given in this study (dog).

    Source sentences

    Summary
    more evident (reversible) adverse effects (liver and kidney findings, anaemia, clinical chemistry changes, organ weight effects) were observed in dogs after repeat daily subcutaneous injections
  12. 12AnimalAnimal study (in vivo)Pharmacokinetics

    In rats and dogs, exposure to immunoreactive TH9507 was dose related after both routes of administration.

    In plain wordsIn rats and dogs, the amount of TH9507 in the blood rose with the dose for both injection routes.

    Peptide
    Tesamorelin
    Outcome
    IncreaseExposure to immunoreactive TH9507
    Study

    rat and dogn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenous or subcutaneousAs given in this study (rat and dog).

    Source sentences

    Summary
    In both rats and dogs, toxicokinetic evaluations indicated that exposure to immunoreactive TH9507 was dose related after both routes of administration.
  13. 13AnimalAnimal study (in vivo)Pharmacokinetics

    In dogs, the apparent elimination half-life of TH9507 ranged from 21 to 45 min.

    In plain wordsIn dogs, the half-life of TH9507 in the body ranged from 21 to 45 minutes.

    Peptide
    Tesamorelin
    Outcome
    Not applicableApparent elimination half-life in dogs
    Study

    dogn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Apparent elimination t1/2
    21 to 45 min
    dogs

    Source sentences

    Summary
    The apparent elimination t1/2 in dogs ranged from 21 to 45 min.
  14. 14LabEx vivo tissuePharmacokinetics

    In rat, dog and human plasma in vitro, TH9507 degraded more slowly than natural hGRF1-44NH2.

    In plain wordsIn lab tests with rat, dog and human plasma, TH9507 broke down more slowly than the natural peptide.

    Peptide
    Tesamorelin
    Outcome
    DecreaseIn vitro plasma degradation
    Study

    rat, dog and humann: not reported in source

    plasma
    Comparator
    Natural hGRF1-44NH2
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to natural hGRF1-44NH2, the modification slowed the in vitro degradation of the peptide in rat, dog and human plasma
  15. 15LabIn vitro (cell-free)Pharmacokinetics

    In lab tests, TH9507 (tesamorelin) was resistant to dipeptidyl aminopeptidase-IV deactivation.

    In plain wordsIn lab tests, TH9507 resisted breakdown by the enzyme dipeptidyl aminopeptidase-IV.

    Peptide
    Tesamorelin
    Outcome
    No significant changeResistance to DPP-IV deactivation
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    was found to be resistant to dipeptidyl aminopeptidase-IV deactivation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.